Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 250

1.

Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method.

Winnicki W, Sunder-Plassmann G, Sengölge G, Handisurya A, Herkner H, Kornauth C, Bielesz B, Wagner L, Kikić Ž, Pajenda S, Reiter T, Schairer B, Schmidt A.

Sci Rep. 2019 Sep 24;9(1):13783. doi: 10.1038/s41598-019-50405-8.

2.

First case of late onset cardiac phenotype Fabry disease due to an AluYb8 insertion in exon 7 of the GLA gene.

Gatterer C, Beitzke D, Sunder-Plassmann R, Sunder-Plassmann G, Graf S.

Eur Heart J Cardiovasc Imaging. 2019 Oct 1;20(10):1182. doi: 10.1093/ehjci/jez083. No abstract available.

PMID:
31329829
3.

A non-randomized trial of conversion from ciclosporin and tacrolimus to tacrolimus MR4 in stable long-term kidney transplant recipients: Graft function and influences of ABCB1 genotypes.

Riegersperger M, Plischke M, Jallitsch-Halper A, Steinhauser C, Födinger M, Winkelmayer WC, Dunkler D, Sunder-Plassmann G.

PLoS One. 2019 Jul 2;14(7):e0218709. doi: 10.1371/journal.pone.0218709. eCollection 2019.

4.

An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy.

Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G.

Clin Kidney J. 2019 Apr 21;12(3):333-337. doi: 10.1093/ckj/sfz040. eCollection 2019 Jun.

5.

Oral Sodium Bicarbonate Supplementation Does Not Affect Serum Calcification Propensity in Patients with Chronic Kidney Disease and Chronic Metabolic Acidosis.

Aigner C, Cejka D, Sliber C, Fraunschiel M, Sunder-Plassmann G, Gaggl M.

Kidney Blood Press Res. 2019;44(2):188-199. doi: 10.1159/000498975. Epub 2019 May 8.

6.

Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study.

Hughes DA, Nicholls K, Sunder-Plassmann G, Jovanovic A, Feldt-Rasmussen U, Schiffmann R, Giugliani R, Jain V, Viereck C, Castelli JP, Skuban N, Barth JA, Bichet DG.

Am J Med Genet A. 2019 Jun;179(6):1069-1073. doi: 10.1002/ajmg.a.61105. Epub 2019 Mar 28. No abstract available.

7.

Kidney Injury by Variants in the COL4A5 Gene Aggravated by Polymorphisms in Slit Diaphragm Genes Causes Focal Segmental Glomerulosclerosis.

Frese J, Kettwig M, Zappel H, Hofer J, Gröne HJ, Nagel M, Sunder-Plassmann G, Kain R, Neuweiler J, Gross O.

Int J Mol Sci. 2019 Jan 26;20(3). pii: E519. doi: 10.3390/ijms20030519.

8.

Magnetic resonance imaging T1- and T2-mapping to assess renal structure and function: a systematic review and statement paper.

Wolf M, de Boer A, Sharma K, Boor P, Leiner T, Sunder-Plassmann G, Moser E, Caroli A, Jerome NP.

Nephrol Dial Transplant. 2018 Sep 1;33(suppl_2):ii41-ii50. doi: 10.1093/ndt/gfy198.

9.

Maternal and Fetal Outcomes of Pregnancies in Women with Atypical Hemolytic Uremic Syndrome.

Gaggl M, Aigner C, Csuka D, Szilágyi Á, Prohászka Z, Kain R, Haninger N, Knechtelsdorfer M, Sunder-Plassmann R, Sunder-Plassmann G, Schmidt A.

J Am Soc Nephrol. 2018 Mar;29(3):1020-1029. doi: 10.1681/ASN.2016090995. Epub 2017 Dec 27.

10.

Manifestations of neurological symptoms and thromboembolism in adults with MTHFR-deficiency.

Rommer PS, Zschocke J, Fowler B, Födinger M, Konstantopoulou V, Möslinger D, Stögmann E, Suess E, Baumgartner M, Auff E, Sunder-Plassmann G.

J Neurol Sci. 2017 Dec 15;383:123-127. doi: 10.1016/j.jns.2017.10.035. Epub 2017 Nov 6.

PMID:
29246599
11.

Taurolidine-based catheter lock regimen significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters.

Winnicki W, Herkner H, Lorenz M, Handisurya A, Kikić Ž, Bielesz B, Schairer B, Reiter T, Eskandary F, Sunder-Plassmann G, Sengoelge G.

Kidney Int. 2018 Mar;93(3):753-760. doi: 10.1016/j.kint.2017.06.026. Epub 2017 Sep 8.

PMID:
28890326
12.

Blood volume-monitored regulation of ultrafiltration to decrease the dry weight in fluid-overloaded hemodialysis patients: a randomized controlled trial.

Antlanger M, Josten P, Kammer M, Exner I, Lorenz-Turnheim K, Eigner M, Paul G, Klauser-Braun R, Sunder-Plassmann G, Säemann MD, Hecking M.

BMC Nephrol. 2017 Jul 17;18(1):238. doi: 10.1186/s12882-017-0639-x.

13.

CORRIGENDUM: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.

van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Kriek M, Mitropoulou C, Patrinos GP, Pirmohamed M, Samwald M, Schaeffeler E, Schwab M, Steinberger D, Stingl J, Sunder-Plassmann G, Toffoli G, Turner RM, van Rhenen MH, Swen JJ, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium.

Clin Pharmacol Ther. 2017 Jul;102(1):152. doi: 10.1002/cpt.725. No abstract available.

PMID:
30239993
14.

The Effect of ABCB1 Polymorphisms on Serial Tacrolimus Concentrations in Stable Austrian Long-Term Kidney Transplant Recipients.

Riegersperger M, Plischke M, Steinhauser C, Jallitsch-Halper A, Sengoelge G, Winkelmayer WC, Sunder-Plassmann G, Födinger M.

Clin Lab. 2016 Oct 1;62(10):1965-1972. doi: 10.7754/Clin.Lab.2016.160221.

PMID:
28164520
15.

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.

van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Kriek M, Mitropoulou C, Patrinos GP, Pirmohamed M, Samwald M, Schaeffeler E, Schwab M, Steinberger D, Stingl J, Sunder-Plassmann G, Toffoli G, Turner RM, van Rhenen MH, Swen JJ, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium.

Clin Pharmacol Ther. 2017 Mar;101(3):341-358. doi: 10.1002/cpt.602. Erratum in: Clin Pharmacol Ther. 2017 Jul;102(1):152.

PMID:
28027596
16.

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.

Hughes DA, Nicholls K, Shankar SP, Sunder-Plassmann G, Koeller D, Nedd K, Vockley G, Hamazaki T, Lachmann R, Ohashi T, Olivotto I, Sakai N, Deegan P, Dimmock D, Eyskens F, Germain DP, Goker-Alpan O, Hachulla E, Jovanovic A, Lourenco CM, Narita I, Thomas M, Wilcox WR, Bichet DG, Schiffmann R, Ludington E, Viereck C, Kirk J, Yu J, Johnson F, Boudes P, Benjamin ER, Lockhart DJ, Barlow C, Skuban N, Castelli JP, Barth J, Feldt-Rasmussen U.

J Med Genet. 2017 Apr;54(4):288-296. doi: 10.1136/jmedgenet-2016-104178. Epub 2016 Nov 10. Erratum in: J Med Genet. 2018 Apr 16;:.

17.

Fabry disease: A pharmacological chaperone on the horizon.

Gaggl M, Sunder-Plassmann G.

Nat Rev Nephrol. 2016 Nov;12(11):653-654. doi: 10.1038/nrneph.2016.138. Epub 2016 Sep 26. No abstract available.

PMID:
27665929
18.

[Thrombotic microangiopathy : Relevant new aspects for intensive care physicians].

Gaggl M, Aigner C, Sunder-Plassmann G, Schmidt A.

Med Klin Intensivmed Notfmed. 2016 Jun;111(5):434-9. doi: 10.1007/s00063-016-0176-6. Epub 2016 Jun 2. German.

PMID:
27255224
19.

Screening for Fabry Disease by Urinary Globotriaosylceramide Isoforms Measurement in Patients with Left Ventricular Hypertrophy.

Gaggl M, Lajic N, Heinze G, Voigtländer T, Sunder-Plassmann R, Paschke E, Fauler G, Sunder-Plassmann G, Mundigler G.

Int J Med Sci. 2016 Apr 26;13(5):340-6. doi: 10.7150/ijms.14997. eCollection 2016.

20.

The Renal History of Fabry Disease.

Gaggl M, El-Hadi S, Aigner C, Sunder-Plassmann G.

G Ital Nefrol. 2016 Feb;33 Suppl 66:33.S66.14.

21.

Late Conversion of Kidney Transplant Recipients from Ciclosporin to Tacrolimus Improves Graft Function: Results from a Randomized Controlled Trial.

Plischke M, Riegersperger M, Dunkler D, Heinze G, Kikić Ž, Winkelmayer WC, Sunder-Plassmann G.

PLoS One. 2015 Aug 13;10(8):e0135674. doi: 10.1371/journal.pone.0135674. eCollection 2015.

22.

Pulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (Vienna RAP Study): study protocol for a randomized controlled trial.

Riegersperger M, Herkner H, Sunder-Plassmann G.

Trials. 2015 Apr 23;16:182. doi: 10.1186/s13063-015-0692-3.

23.

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.

Biegstraaten M, Arngrímsson R, Barbey F, Boks L, Cecchi F, Deegan PB, Feldt-Rasmussen U, Geberhiwot T, Germain DP, Hendriksz C, Hughes DA, Kantola I, Karabul N, Lavery C, Linthorst GE, Mehta A, van de Mheen E, Oliveira JP, Parini R, Ramaswami U, Rudnicki M, Serra A, Sommer C, Sunder-Plassmann G, Svarstad E, Sweeb A, Terryn W, Tylki-Szymanska A, Tøndel C, Vujkovac B, Weidemann F, Wijburg FA, Woolfson P, Hollak CE.

Orphanet J Rare Dis. 2015 Mar 27;10:36. doi: 10.1186/s13023-015-0253-6.

24.

Interfering parameters in the determination of urinary globotriaosylceramide (Gb3) in patients with chronic kidney disease.

Gaggl M, Hofer M, Weidner S, Kleinert J, Fauler G, Wallner M, Kotanko P, Paschke E, Sunder-Plassmann G.

J Nephrol. 2015 Dec;28(6):679-89. doi: 10.1007/s40620-015-0193-1. Epub 2015 Apr 10.

PMID:
25857295
25.

Effect of oral alkali supplementation on progression of chronic kidney disease.

Gaggl M, Sliber C, Sunder-Plassmann G.

Curr Hypertens Rev. 2014;10(2):112-20. Review.

PMID:
25549843
26.

Sex-specific differences in hemodialysis prevalence and practices and the male-to-female mortality rate: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Hecking M, Bieber BA, Ethier J, Kautzky-Willer A, Sunder-Plassmann G, Säemann MD, Ramirez SP, Gillespie BW, Pisoni RL, Robinson BM, Port FK.

PLoS Med. 2014 Oct 28;11(10):e1001750. doi: 10.1371/journal.pmed.1001750. eCollection 2014 Oct.

27.

A SAGE based approach to human glomerular endothelium: defining the transcriptome, finding a novel molecule and highlighting endothelial diversity.

Sengoelge G, Winnicki W, Kupczok A, von Haeseler A, Schuster M, Pfaller W, Jennings P, Weltermann A, Blake S, Sunder-Plassmann G.

BMC Genomics. 2014 Aug 27;15:725. doi: 10.1186/1471-2164-15-725.

28.

Correlations and time course of FGF23 and markers of bone metabolism in maintenance hemodialysis patients.

Bielesz BO, Hecking M, Plischke M, Cejka D, Kieweg H, Haas M, Marculescu R, Hörl WH, Bieglmayer C, Sunder-Plassmann G.

Clin Biochem. 2014 Sep;47(13-14):1316-9. doi: 10.1016/j.clinbiochem.2014.06.009. Epub 2014 Jun 21.

PMID:
24956265
29.

Dialysate sodium prescription and blood pressure in hemodialysis patients.

Hecking M, Karaboyas A, Rayner H, Saran R, Sen A, Inaba M, Bommer J, Hörl WH, Pisoni RL, Robinson BM, Sunder-Plassmann G, Port FK.

Am J Hypertens. 2014 Sep;27(9):1160-9. doi: 10.1093/ajh/hpu040. Epub 2014 Mar 20.

PMID:
24651636
30.

Significance of interdialytic weight gain versus chronic volume overload: consensus opinion.

Hecking M, Karaboyas A, Antlanger M, Saran R, Wizemann V, Chazot C, Rayner H, Hörl WH, Pisoni RL, Robinson BM, Sunder-Plassmann G, Moissl U, Kotanko P, Levin NW, Säemann MD, Kalantar-Zadeh K, Port FK, Wabel P.

Am J Nephrol. 2013;38(1):78-90. doi: 10.1159/000353104. Epub 2013 Jul 6.

31.

Effect of oral sodium bicarbonate supplementation on progression of chronic kidney disease in patients with chronic metabolic acidosis: study protocol for a randomized controlled trial (SoBic-Study).

Gaggl M, Cejka D, Plischke M, Heinze G, Fraunschiel M, Schmidt A, Hörl WH, Sunder-Plassmann G.

Trials. 2013 Jul 4;14:196. doi: 10.1186/1745-6215-14-196.

32.

A single lung transplant in a patient with fabry disease: causality or far-fetched? A case report.

Gaggl M, Kain R, Jaksch P, Haider D, Mundigler G, Voigtländer T, Sunder-Plassmann R, Rommer P, Klepetko W, Sunder-Plassmann G.

Case Rep Transplant. 2013;2013:905743. doi: 10.1155/2013/905743. Epub 2013 Apr 7.

33.

Effect of conversion from ciclosporin to tacrolimus on endothelial progenitor cells in stable long-term kidney transplant recipients.

Riegersperger M, Plischke M, Steiner S, Seidinger D, Sengoelge G, Winkelmayer WC, Sunder-Plassmann G.

Transplantation. 2013 Jun 15;95(11):1338-45. doi: 10.1097/TP.0b013e31828fabb3.

PMID:
23594858
34.

Renal function in heart failure: a disparity between estimating function and predicting mortality risk.

Plischke M, Neuhold S, Kohl M, Heinze G, Sunder-Plassmann G, Pacher R, Hülsmann M.

Eur J Heart Fail. 2013 Jul;15(7):763-70. doi: 10.1093/eurjhf/hft022. Epub 2013 Feb 20.

35.

Clinical evaluation of two novel biointact PTH(1-84) assays in hemodialysis patients.

Hecking M, Kainz A, Bielesz B, Plischke M, Beilhack G, Hörl WH, Sunder-Plassmann G, Bieglmayer C.

Clin Biochem. 2012 Dec;45(18):1645-51. doi: 10.1016/j.clinbiochem.2012.08.006. Epub 2012 Aug 11.

36.

Randomized, single blind, controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in renal transplant recipients.

Tobudic S, Plunger V, Sunder-Plassmann G, Riegersperger M, Burgmann H.

PLoS One. 2012;7(9):e46133. doi: 10.1371/journal.pone.0046133. Epub 2012 Sep 28.

37.

Kidney transplantation and enzyme replacement therapy in patients with Fabry disease.

Cybulla M, Kurschat C, West M, Nicholls K, Torras J, Sunder-Plassmann G, Feriozzi S.

J Nephrol. 2013 Jul-Aug;26(4):645-51. doi: 10.5301/jn.5000214. Epub 2012 Sep 19. Review.

PMID:
23023720
38.

Lisinopril pharmacokinetics and erythropoietin requirement in haemodialysis patients.

Winnicki W, Prehslauer A, Kletzmayr J, Herkner H, Sunder-Plassmann G, Brunner M, Hörl WH, Sengoelge G.

Eur J Clin Invest. 2012 Oct;42(10):1087-93. doi: 10.1111/j.1365-2362.2012.02699.x. Epub 2012 Jul 28.

PMID:
22845880
39.

Epidemiology of uromodulin-associated kidney disease - results from a nation-wide survey.

Lhotta K, Piret SE, Kramar R, Thakker RV, Sunder-Plassmann G, Kotanko P.

Nephron Extra. 2012 Jan;2(1):147-58. doi: 10.1159/000339102. Epub 2012 Jun 1.

40.

Blood volume-monitored regulation of ultrafiltration in fluid-overloaded hemodialysis patients: study protocol for a randomized controlled trial.

Hecking M, Antlanger M, Winnicki W, Reiter T, Werzowa J, Haidinger M, Weichhart T, Polaschegg HD, Josten P, Exner I, Lorenz-Turnheim K, Eigner M, Paul G, Klauser-Braun R, Hörl WH, Sunder-Plassmann G, Säemann MD.

Trials. 2012 Jun 8;13:79. doi: 10.1186/1745-6215-13-79.

41.

Comparative pharmacokinetic study of two mycophenolate mofetil formulations in stable kidney transplant recipients.

Sunder-Plassmann G, Reinke P, Rath T, Wiecek A, Nowicki M, Moore R, Lutz J, Gaggl M, Ferkl M.

Transpl Int. 2012 Jun;25(6):680-6. doi: 10.1111/j.1432-2277.2012.01475.x. Epub 2012 Apr 16.

42.

The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.

Feriozzi S, Torras J, Cybulla M, Nicholls K, Sunder-Plassmann G, West M; FOS Investigators.

Clin J Am Soc Nephrol. 2012 Jan;7(1):60-9. doi: 10.2215/CJN.03130411.

43.

Cardiovascular disease mortality in kidney transplant recipients: no light at the end of the tunnel?

Sunder-Plassmann G, Födinger M, Säemann MD.

Am J Kidney Dis. 2012 Jun;59(6):754-7. doi: 10.1053/j.ajkd.2011.11.022. Epub 2011 Dec 16. No abstract available.

PMID:
22177656
44.

Dialysate sodium concentration and the association with interdialytic weight gain, hospitalization, and mortality.

Hecking M, Karaboyas A, Saran R, Sen A, Inaba M, Rayner H, Hörl WH, Pisoni RL, Robinson BM, Sunder-Plassmann G, Port FK.

Clin J Am Soc Nephrol. 2012 Jan;7(1):92-100. doi: 10.2215/CJN.05440611. Epub 2011 Nov 3.

45.

Predialysis serum sodium level, dialysate sodium, and mortality in maintenance hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Hecking M, Karaboyas A, Saran R, Sen A, Hörl WH, Pisoni RL, Robinson BM, Sunder-Plassmann G, Port FK.

Am J Kidney Dis. 2012 Feb;59(2):238-48. doi: 10.1053/j.ajkd.2011.07.013. Epub 2011 Sep 23.

PMID:
21944663
46.

Impact of measures to enhance the value of observational surveys in rare diseases: the Fabry Outcome Survey (FOS).

Clarke JT, Giugliani R, Sunder-Plassmann G, Elliott PM, Pintos-Morell G, Hernberg-Ståhl E, Malmenäs M, Beck M; FOS Investigators.

Value Health. 2011 Sep-Oct;14(6):862-6. doi: 10.1016/j.jval.2011.05.002. Epub 2011 Jun 23.

47.

The endocardial binary appearance ('binary sign') is an unreliable marker for echocardiographic detection of Fabry disease in patients with left ventricular hypertrophy.

Mundigler G, Gaggl M, Heinze G, Graf S, Zehetgruber M, Lajic N, Voigtländer T, Mannhalter C, Sunder-Plassmann R, Paschke E, Fauler G, Sunder-Plassmann G.

Eur J Echocardiogr. 2011 Oct;12(10):744-9. doi: 10.1093/ejechocard/jer112. Epub 2011 Aug 20.

PMID:
21857019
48.

Concluding remarks.

Mehta A, Beck M, Linhart A, Sunder-Plassmann G.

In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 44.

49.

History of lysosomal storage diseases: an overview.

Mehta A, Beck M, Linhart A, Sunder-Plassmann G, Widmer U.

In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 1.

50.

Diagnosis of Fabry disease: the role of screening and case-finding studies.

Sunder-Plassmann G, Födinger M.

In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 17.

Supplemental Content

Loading ...
Support Center